Literature DB >> 15028070

Long-term follow-up of right atrial ablation in patients with atrial fibrillation:.

Leonardo Calò1, Filippo Lamberti, Maria Luisa Loricchio, Antonio Castro, Shlomo Shpun, Augusto Boggi, Claudio Pandozi, Massimo Santini.   

Abstract

INTRODUCTION: The aim of this study was to evaluate the efficacy and the impact on quality of life of a new ablative approach to the right atrium in patients with atrial fibrillation (AF). METHODS AND
RESULTS: Seventy-four symptomatic patients with paroxysmal (n = 49) or permanent (n = 25) refractory AF underwent radiofrequency ablation. A nonfluoroscopic electroanatomic mapping system was used to perform the following lesions: (1) an isthmus line between the tricuspid annulus and the inferior vena cava; (2) a posterior intercaval line from the superior vena cava and the inferior vena cava; (3) a septal line from the superior vena cava to the fossa ovalis, proceeding to the coronary sinus ostium where a circumferential line around the ostium was performed, and then on to the inferior vena cava; and (4) a transversal lesion connecting the posterior intercaval and the septal lesions. In addition, electrical disconnection of the superior vena cava was performed. There were no complications. Postablation remapping showed the absence of discrete electrical activity inside and just around the ablation lines. Electrical disconnection of the superior vena cava was obtained in all patients. After 21 +/- 6 months, 49 patients (66%) had stable sinus rhythm with continuation of the previous antiarrhythmic drug therapy, 13 patients (18%) were considered improved, and 12 (16%) received no benefit (unsuccessful procedure). After ablation, quality of life was significantly improved, reaching the levels of the general Italian population. Ejection fraction and the extent of the low-voltage area were found by multivariate analysis to be independent predictors of AF recurrence.
CONCLUSION: The results of the present study suggest that this ablative approach in combination with antiarrhythmic drugs is safe and effective in treating AF, leading to a marked increase in quality of life in patients with refractory AF.

Entities:  

Mesh:

Year:  2004        PMID: 15028070     DOI: 10.1046/j.1540-8167.2004.03264.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  5 in total

1.  Catheter ablation of permanent atrial fibrillation: medium term results.

Authors:  M J Earley; D J R Abrams; A D Staniforth; S C Sporton; R J Schilling
Journal:  Heart       Date:  2005-08-23       Impact factor: 5.994

2.  Polymorphism rs2200733 at chromosome 4q25 is associated with atrial fibrillation recurrence after radiofrequency catheter ablation in the Chinese Han population.

Authors:  Feifei Chen; Yanzong Yang; Rongfeng Zhang; Shulong Zhang; Yingxue Dong; Xiaomeng Yin; Dong Chang; Zhiqiang Yang; Kejing Wang; Lianjun Gao; Yunlong Xia
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

3.  Disparate evolution of right and left atrial rate during ablation of long-lasting persistent atrial fibrillation.

Authors:  Mélèze Hocini; Isabelle Nault; Matthew Wright; George Veenhuyzen; Sanjiv M Narayan; Pierre Jaïs; Kang-Teng Lim; Sébastien Knecht; Seiichiro Matsuo; Andrei Forclaz; Shinsuke Miyazaki; Amir Jadidi; Mark D O'Neill; Frédéric Sacher; Jacques Clémenty; Michel Haïssaguerre
Journal:  J Am Coll Cardiol       Date:  2010-03-09       Impact factor: 24.094

4.  Survey of physician experience, trends and outcomes with atrial fibrillation ablation.

Authors:  Steven Mickelsen; Ben Dudley; Eric Treat; John Barela; John Omdahl; Fred Kusumoto
Journal:  J Interv Card Electrophysiol       Date:  2005-04       Impact factor: 1.900

5.  Hybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation.

Authors:  Abraham G Kocheril; Hugh Calkins; Arjun D Sharma; Daniel Cher; Harrison A Stubbs; Jon E Block
Journal:  J Interv Card Electrophysiol       Date:  2005-04       Impact factor: 1.900

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.